Cargando…

Clinical efficacy of neoadjuvant chemotherapy regimens FLEEOX vs. XELOX in patients with initially unresectable advanced gastric cancer: a propensity score analysis

PURPOSE: This study was designed to assess the effectiveness of FLEEOX (5-Fu, leucovorin, etoposide, oxaliplatin, and epirubicin) compared with XELOX (capecitabine and oxaliplatin) as neoadjuvant chemotherapy (NAC) for initially unresectable advanced gastric cancer (AGC). METHODS: This study reviewe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yang, Chen, Jun, He, Qi, Ji, Xiang, Wang, Xulin, Fan, Chaogang, Li, Guoli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689733/ https://www.ncbi.nlm.nih.gov/pubmed/29156843 http://dx.doi.org/10.18632/oncotarget.19004

Ejemplares similares

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer
por: Li, Yang, et al.
Publicado: (2018)

Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2019)

Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer
por: Zhang, Caihua, et al.
Publicado: (2012)

Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
por: Yin, Xin, et al.
Publicado: (2020)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
por: Yu, Shan, et al.
Publicado: (2020)

Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis
por: Chen, Yonghe, et al.
Publicado: (2021)

Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study
por: Li, Yang, et al.
Publicado: (2020)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
por: Guo, Honghai, et al.
Publicado: (2022)

Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia
por: Li, Quanfu, et al.
Publicado: (2021)

Propensity-score-matching-based analysis of laparoscopic gastrectomy with neoadjuvant chemotherapy for gastric carcinoma
por: Furuta, Shimpei, et al.
Publicado: (2021)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019)

Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma: A case report
por: Lin, Zhixian, et al.
Publicado: (2019)

Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis
por: Zhang, Xin, et al.
Publicado: (2020)

The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer
por: Chen, Jun-Bing, et al.
Publicado: (2022)

Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis
por: Zhang, Xin, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal
por: Joshi, Amit, et al.
Publicado: (2015)

Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
por: Wang, Yan, et al.
Publicado: (2018)

Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy
por: Powell, A. G. M. T., et al.
Publicado: (2020)

Laparoscopic vs open total gastrectomy for advanced gastric cancer following neoadjuvant therapy: A propensity score matching analysis
por: Hu, Hai-Tao, et al.
Publicado: (2022)

Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?: A PRISMA-compliant network meta-analysis
por: Zhang, Dan, et al.
Publicado: (2018)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Stent placement above the sphincter of Oddi permits implementation of neoadjuvant chemotherapy in patients with initially unresectable Klatskin tumor
por: Kubota, Kensuke, et al.
Publicado: (2016)

Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis
por: Li, Jing, et al.
Publicado: (2021)

Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer
por: Yu, Yuanyuan, et al.
Publicado: (2022)

Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)
por: Chen, Yizhang, et al.
Publicado: (2023)

Efficacy and Safety of Neoadjuvant Chemotherapy Combined with Adjuvant Chemotherapy for Locally Advanced Colon Cancer: A Propensity Score-Matching Analysis
por: Zeng, Wei, et al.
Publicado: (2022)

Expression Profiles of Circulating MicroRNAs in XELOX-Chemotherapy-Induced Peripheral Neuropathy in Patients with Advanced Gastric Cancer
por: Ju, Yeongdon, et al.
Publicado: (2022)

Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study
por: Li, Hui-Zhou, et al.
Publicado: (2021)

XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)
por: Zhu, Xiao‐Dong, et al.
Publicado: (2022)

Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
por: Zhao, Junfeng, et al.
Publicado: (2023)

Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school
por: Ungari, Andrea Queiróz, et al.
Publicado: (2017)

Curative surgical resection for initially unresectable metastatic gallbladder cancer following neoadjuvant chemotherapy: Case report and review of literature
por: Al Jaber, Fatimah, et al.
Publicado: (2022)

Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis
por: Kano, Masayuki, et al.
Publicado: (2019)

Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
por: Lee, Jaejun, et al.
Publicado: (2021)

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
por: Iwasaki, Hiroyuki, et al.
Publicado: (2020)

Neoadjuvant chemotherapy in technically unresectable head and neck cancers: a retrospective audit
por: Mishra, Bal Krishna, et al.
Publicado: (2022)

Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma—A Propensity Score Weighted Comparison of Efficacy and Safety
por: Savic, Lynn Jeanette, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1palo9k17k8qq0oo6i21m8iugp